OncoMatch/Clinical Trials/NCT06541444

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Is NCT06541444 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies NK520 for relapsed/refractory acute myeloid leukemia.

Early Phase 1RecruitingBase Therapeutics (Shanghai) Co., Ltd.NCT06541444Data as of May 2026

Treatment: NK520 — This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 2 prior lines

Lab requirements

Blood counts

Normal Organ Function

Kidney function

Normal Organ Function

Liver function

Normal Organ Function

Normal Organ Function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify